Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified

Jessica J. Wyse, Benjamin J. Morasco, Steven K. Dobscha, Michael I. Demidenko, Thomas H.A. Meath, Travis I. Lovejoy

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified'. Together they form a unique fingerprint.

Medicine & Life Sciences